A neurovascular high-frequency optical coherence tomography system enables in situ cerebrovascular volumetric microscopy
- PMID:32737314
- PMCID: PMC7395105
- DOI: 10.1038/s41467-020-17702-7
A neurovascular high-frequency optical coherence tomography system enables in situ cerebrovascular volumetric microscopy
Abstract
Intravascular imaging has emerged as a valuable tool for the treatment of coronary and peripheral artery disease; however, no solution is available for safe and reliable use in the tortuous vascular anatomy of the brain. Endovascular treatment of stroke is delivered under image guidance with insufficient resolution to adequately assess underlying arterial pathology and therapeutic devices. High-resolution imaging, enabling surgeons to visualize cerebral arteries' microstructure and micron-level features of neurovascular devices, would have a profound impact in the research, diagnosis, and treatment of cerebrovascular diseases. Here, we present a neurovascular high-frequency optical coherence tomography (HF-OCT) system, including an imaging console and an endoscopic probe designed to rapidly acquire volumetric microscopy data at a resolution approaching 10 microns in tortuous cerebrovascular anatomies. Using a combination of in vitro, ex vivo, and in vivo models, the feasibility of HF-OCT for cerebrovascular imaging was demonstrated.
Conflict of interest statement
G.J.U., L.M.P., and B.H.D. are employees of Gentuity LLC and hold stocks. M.G.M. is a consultant on a fee-per-hour basis for InNeuroCo In and Stryker Neurovascular. D.K.L. has received research support from Medtronic Neurovascular. M.J.G. has received research support from the National Institutes of Health (NIH), the United States–Israel Binational Science Foundation, Anaconda, Apic Bio, Arsenal Medical, Axovant, Cerenovus, Ceretrieve, Cook Medical, Galaxy LLC, Gentuity, Imperative Care, InNeuroCo, Insera, Magneto, Microvention, Medtronic Neurovascular, MIVI Neurosciences, Neuravi, Neurogami, Philips Healthcare, Progressive Neuro, Rapid Medical, Route 92 Medical, Stryker Neurovascular, Syntheon, and the Wyss Institute; is a consultant on a fee-per-hour basis for Cerenovus, Imperative Care, Medtronic Neurovascular, Mivi Neurosciences, Phenox, Route 92 Medical, and Stryker Neurovascular; holds stock in Imperative Care, InNeuroCo, and Neurogami. A.S.P. has been a proctor on a fee-per-hour basis for Stryker Neurovascular, and Cerenovus; has research grants from Cerenovus, Medtronic Neurovascular, and Stryker Neurovascular; holds stock in InNeuroCo, and NTI. The remaining authors declare no competing interests.
Figures








References
- Becske T, et al. Pipeline for uncoilable or failed aneurysms: results from a multicenter clinical trial. Radiology. 2013;267:858–868. - PubMed
- Heller R, Calnan DR, Lanfranchi M, Madan N, Malek AM. Incomplete stent apposition in Enterprise stent-mediated coiling of aneurysms: persistence over time and risk of delayed ischemic events. J. Neurosurg. 2013;118:1014–1022. - PubMed
- Mocco J, et al. Treatment of intracranial aneurysms with the Enterprise stent: a multicenter registry. J. Neurosurg. 2009;110:35–39. - PubMed
- Campbell BCV, et al. Endovascular stent thrombectomy: the new standard of care for large vessel ischaemic stroke. Lancet Neurol. 2015;14:846–854. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
